(UroToday.com) The European Society of Medical Oncology (ESMO) 2021 annual meeting’s prostate cancer session included a presentation by Dr. Neeraj Agarwal discussing the TALAPRO-3 trial concept and design, a phase 3 trial assessing enzalutamide plus talazoparib versus placebo plus enzalutamide in men with DDR gene mutated metastatic castration-sensitive prostate cancer. Treatment for metastatic castration-sensitive prostate cancer (mCSPC) should be individualized to the patient, but one standard-of-care therapy involves androgen deprivation therapy (ADT) in combination with an androgen axis inhibitor, such as enzalutamide. Talazoparib is a poly (ADP-ribose) polymerase (PARP) inhibitor approved as monotherapy for germline BRCA1/2-mutated HER2- negative advanced breast cancer. PARP inhibitors have demonstrated substantial clinical efficacy in homologous recombination repair (HRR)/DNA damage response (DDR)-altered metastatic castration-resistant prostate cancers (mCRPC).